Published in J Immunol on April 01, 1994
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A (2012) 3.50
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest (1995) 2.66
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol (1997) 2.50
Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) (2010) 2.48
Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46
Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol (2000) 2.23
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest (2004) 1.65
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog (2013) 1.65
Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol (2002) 1.56
Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, lpr, and Bcl-2-transgenic mice. Am J Pathol (1995) 1.48
Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol (2003) 1.39
Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog (2011) 1.34
Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2002) 1.29
Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol (2007) 1.27
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol (1995) 1.25
Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett (2010) 1.22
HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol (2007) 1.20
The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol (2007) 1.16
Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol (2003) 1.11
Immunopathogenic role of T-cell subsets in Borna disease virus-induced progressive encephalitis. J Virol (1995) 1.09
CC chemokine ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following viral infection. J Virol (2003) 1.09
A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol (2008) 1.04
Inflammation and repair in viral hepatitis C. Dig Dis Sci (2008) 0.94
Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol (2012) 0.93
Liver infiltrating T lymphocytes express interferon gamma and inducible nitric oxide synthase in chronic hepatitis C virus infection. Gut (2000) 0.92
The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection. Front Immunol (2014) 0.91
Polyfunctional type-1, -2, and -17 CD8⁺ T cell responses to apoptotic self-antigens correlate with the chronic evolution of hepatitis C virus infection. PLoS Pathog (2012) 0.89
Intracellular hepatitis B virus nucleocapsids survive cytotoxic T-lymphocyte-induced apoptosis. J Virol (2000) 0.89
Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Immunology (2014) 0.89
Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections. J Virol (2011) 0.87
Plasmodium cellular effector mechanisms and the hepatic microenvironment. Front Microbiol (2015) 0.84
The sterile inflammation in the exacerbation of HBV-associated liver injury. Mediators Inflamm (2015) 0.83
Praziquantel facilitates IFN-γ-producing CD8+ T cells (Tc1) and IL-17-producing CD8+ T cells (Tc17) responses to DNA vaccination in mice. PLoS One (2011) 0.82
Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest (1995) 0.81
Apoptosis induced by tumor necrosis factor-alpha in rat hepatocyte cell lines expressing hepatitis B virus. Am J Pathol (1996) 0.79
Immune-mediated Liver Injury in Hepatitis B Virus Infection. Immune Netw (2015) 0.78
Boosting immune response to hepatitis B DNA vaccine by coadministration of Prothymosin alpha-expressing plasmid. Clin Diagn Lab Immunol (2005) 0.78
The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunology (2016) 0.78
Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro. J Virol (2015) 0.77
Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice. Cell Mol Immunol (2015) 0.77
Hepatocytes as Immunological Agents. J Immunol (2016) 0.76
Immunoregulation of hepatitis B virus infection--rationale and clinical application. Nagoya J Med Sci (2012) 0.76
Review of cytokine profiles in patients with hepatitis. World J Gastroenterol (2004) 0.76
The CYP2D6 animal model: how to induce autoimmune hepatitis in mice. J Vis Exp (2012) 0.76
Contributions of transgenic mouse studies on the research of hepatitis B virus and hepatitis C virus-induced hepatocarcinogenesis. World J Hepatol (2015) 0.75
Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models? Int J Mol Sci (2016) 0.75
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell (1985) 11.63
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J (1999) 10.82
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 6.78
Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med (1982) 6.56
The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol (1993) 5.88
High-level hepatitis B virus replication in transgenic mice. J Virol (1995) 5.81
Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol (2001) 5.81
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer (1998) 5.40
Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol (1989) 5.39
WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J (1996) 5.24
Isolation and characterization of yeast mutants deficient in adenylate cyclase and cAMP-dependent protein kinase. Proc Natl Acad Sci U S A (1982) 5.04
The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol (1997) 4.76
Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol (1989) 4.70
Differential regulation of mammalian period genes and circadian rhythmicity by cryptochromes 1 and 2. Proc Natl Acad Sci U S A (1999) 4.62
Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol (1985) 4.44
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli. Infect Immun (1991) 4.18
Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J (1997) 4.01
Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med (1984) 4.00
Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 3.93
Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell (1985) 3.81
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell (1989) 3.60
A T cell-independent mechanism of macrophage activation by interferon-gamma. J Immunol (1987) 3.55
Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev (1991) 3.49
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet (1998) 3.38
Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med (1995) 3.37
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature (1994) 3.34
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science (1990) 3.26
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Application of immunofluorescent staining on paraffin sections improved by trypsin digestion. Lab Invest (1976) 3.22
Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J Biol Chem (1987) 3.20
Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol (1987) 3.16
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet (1999) 3.12
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med (1989) 3.08
In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun (1992) 3.07
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med (1993) 3.06
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun (1991) 3.04
Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A (1988) 2.99
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 2.99
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol (1986) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Initiation of meiosis in yeast mutants defective in adenylate cyclase and cyclic AMP-dependent protein kinase. Cell (1983) 2.91
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J (1994) 2.82
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Genetic analysis of the role of cAMP in yeast. Yeast (1985) 2.78
Release of nitric oxide during the T cell-independent pathway of macrophage activation. Its role in resistance to Listeria monocytogenes. J Immunol (1993) 2.73
Purification and properties of dextransucrase and invertase from Streptococcus mutans. J Bacteriol (1974) 2.72
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J Immunol (1983) 2.61
Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology (1997) 2.61
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A (1999) 2.60
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57